Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins

@article{Banik2019LysosomeTC,
  title={Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins},
  author={Steven M. Banik and Kayvon Pedram and Simon P. Wisnovsky and Nicholas M. Riley and Carolyn R. Bertozzi},
  journal={ChemRxiv},
  year={2019}
}
Targeted protein degradation is a powerful strategy to address the canonically undruggable proteome. However, current technologies are limited to targets with cytosolically-accessible and ligandable domains. Here, we designed and synthesized conjugates capable of binding both a cell surface lysosome targeting receptor and the extracellular domain of a target protein. These lysosome targeting chimeras (LYTACs) consist of an antibody fused to agonist glycopeptide ligands for the cation… 
View PDF
20 Citations
Highly Influential Citations
1
Background Citations
5

Figures from this paper

20 Citations

Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation

GalNAc-LYTACs are developed that engage the asialoglycoprotein receptor (ASGPR), a liver-specific lysosomal targeting receptor, to degrade membrane proteins in a tissue-specific manner and represent an exciting new paradigm for cell-type restricted degradation of proteins.

Proteolysis targeting chimeras (PROTACs) for epigenetics research.

Harnessing the Power of Proteolysis for Targeted Protein Inactivation.

Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs

This technique offers reversible on/off switching of protein degradation that is compatible with an intracellular environment and, therefore, could be useful in experimental exploration of biological signaling pathways—such as those crucial for oncogenic signal transduction.

Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology

Why direct targeting of proteins allows unique insights, what is currently feasible in vitro, and how this relates to potential therapeutic applications are addressed are addressed.

Bifunctional chemical probes inducing protein-protein interactions.

Protein degradation technology: a strategic paradigm shift in drug discovery

This review mainly focuses on summarizing the development of protein degradation technologies in recent years, including the rapid and continuous target consumption as well as the stronger pharmacological effects, being a hot topic in current research.

Unifying principles of bifunctional, proximity-inducing small molecules

The chemical and biophysical principles common to all bifunctional, proximity-inducing small molecules are described and the underappreciated diversity of their chemical structures and biological mechanisms are discussed.

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

This Review summarizes recent developments in this field, with a particular focus on the use of degraders as research tools to interrogate complex biological problems.

Selective inhibition of human translation by a drug-like compound that traps terminated protein nascent chains on the ribosome

The structural and functional data support a model in which PF846 inhibits translation termination by inducing allosteric conformational rearrangements in the NC and PTC that suppress peptidyl-tRNA hydrolysis promoted by eRF1, and trap the NC in the ribosome exit tunnel.

References

SHOWING 1-10 OF 51 REFERENCES

Controlled Synthesis of End-Functionalized Mannose-6-phosphate Glycopolypeptides for Lysosome Targeting.

End-functionalized polyvalent mannose-6-phosphate glycopolypeptides with high molecular weights with minimal toxicity to cells in vitro and show exceptional selectivity for trafficking into lysosomes in various cell lines are synthesized via NCA polymerization.

Phthalimide conjugation as a strategy for in vivo target protein degradation

A chemical strategy that promotes ligand-dependent target protein degradation using as an example the transcriptional coactivator BRD4, a protein critical for cancer cell growth and survival is devised.

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

It is shown that MetAP-2 can be tethered to SCFβ-TRCP, ubiquitinated, and degraded in a Protac-1-dependent manner, which may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction.

The dTAG system for immediate and target-specific protein degradation

The dTAG system pairs potent heterobifunctional degraders and extensible tagging strategies to achieve immediate and reversible degradation of divergent proteins, facilitating biological investigation and drug target validation in cells and in mice.

Chemically tunable mucin chimeras assembled on living cells

A rapid and scalable route to synthetic mucin constructs with precisely defined glycan densities and chain lengths established via N-carboxyanhydride polymerization is developed, which are the first synthetic analogs to the authors' knowledge to feature the native α-GalNAc linkage to serine with molecular weights similar to native mucins, solving a nearly 50-year synthetic challenge.

Mannose 6-phosphate receptor targeting and its applications in human diseases.

The synthesis and potential use of high affinity M6P analogues able to target this receptor are highlighted and their potential applications in preventing clinical disorders, which are associated with the activities of other M 6P-proteins involved in wound healing, cell growth or viral infection, are discussed.

Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake.

A chimeric folate receptor is constructed that has the glycosyl-phosphatidylinositol anchor replaced with the transmembrane domain and cytoplasmic tail of the low density lipoprotein receptor and the cells with wild-type receptors delivered 5-methyltetrahydrofolate to the cy toplasm more rapidly than did cells expressing the chimeric receptor.

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Insight is provided into the biology of PD-L1 regulation, a previously unrecognized master regulator of this critical immune checkpoint is identified, and a potential therapeutic target to overcome immune evasion by tumour cells is highlighted.

N-Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen-Presenting Cells through Dectin-1 and Dectin-2.

This work designed and synthesized the first chemically defined ligands for dectin-1 and dectIn-2, which comprised glycopolypeptides bearing mono-, di-, and trisaccharides and were built through polymerization of glycosylated N-carboxyanhydrides.

Exorcising the Exocyst Complex

Current knowledge of exocyst architecture, assembly, regulation and its roles in a variety of cellular trafficking pathways are discussed.
...